BetterThanSPY

Relative Intelligence · Antibody Therapeutics

How Regeneron Pharmaceuticals (REGN) compares with the whole market and its popular alternatives

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on REGN alone. It places REGN (Regeneron Pharmaceuticals, Inc.) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where REGN stands in the market, and of the alternatives worth a closer look.

Period covered: REGN's full trading record, from April 1991 through September 2026. All returns include reinvested dividends. Data as of October 22, 2026.

Data as of October 22, 2026. Full tables and charts read best on a larger screen.

Rank the market against REGN →Chart REGN vs. 22 alternatives →

This page answers the following questions about REGN

Key findings

Not AI-generated

These key findings are generated by our proprietary relative intelligence engine, directly from the data on this page.

How much would $10,000 in REGN have grown?

This chart tracks a hypothetical $10,000 investment in REGN over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of REGN over the same span and REGN's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.

Choose a period

From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 62 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of REGN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.

$10,000$100,000$1M$10M199720022007201220172022$10,000$100,000$1M$10M19972004201120182025
  • AAPL$21M+205,249% total · +30.1% a year
  • GILD$2M+15,614% total · +19.1% a year
  • TJX$958,745+9,487% total · +17.0% a year
  • DHR$777,394+7,674% total · +16.2% a year
  • COST$727,732+7,177% total · +15.9% a year
  • REGN$683,800+6,738% total · +15.7% a year
  • AMGN$526,909+5,169% total · +14.6% a year
  • LLY$396,376+3,864% total · +13.5% a year
  • VRTX$276,941+2,669% total · +12.1% a year
  • SPY (S&P 500)$132,907+1,229% total · +9.3% a year
Change the dates or add tickers to this chart in EasyCompare

From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,015 of the 3,630 stocks and funds worth at least $500 million that traded the whole period ended ahead of REGN; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.

$0$10,000$20,000$30,000$40,000$50,000$60,000202120222023202420252026$0$20,000$40,000$60,000202120222023202420252026
  • LLY$52,411+424% total · +39.3% a year
  • VRTX$28,822+188% total · +23.6% a year
  • EXEL$27,629+176% total · +22.5% a year
  • HALO$27,138+171% total · +22.1% a year
  • GILD$25,496+155% total · +20.6% a year
  • AMGN$23,160+132% total · +18.3% a year
  • SPY (S&P 500)$19,000+90.0% total · +13.7% a year
  • REGN$12,649+26.5% total · +4.8% a year
  • TMO$11,986+19.9% total · +3.7% a year
  • DHR$8,422−15.8% total · −3.4% a year
Change the dates or add tickers to this chart in EasyCompare

REGN at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.

The company

Market value
$84B
Industry
Biotechnology
Price history from
April 1991

Returns

Past 1 year
+40.8%total return
Past 3 years
+3.9%+1.3% a year
Past 5 years
+44.5%+7.6% a year
Past 10 years
+128%+8.6% a year
Best calendar year
+209%2012
Worst calendar year
−46.9%1997
Losing years
10 of 29full calendar years

Risk

Volatility
31.2%typical yearly swing, 5 years
Sharpe ratio
0.39return per unit of risk, 5 years
Worst decline ever
−91.8%Feb 2000 to Apr 2005
From its all-time high
−31.2%below the peak

REGN against the whole market

Where REGN ranks among every stock and fund, and what across the market has done better.

How does REGN rank among all stocks?

This section ranks REGN on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how REGN stacks up against its peers, these rankings show where it stands in the market as a whole.

Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.

MeasureREGNRankStanding
1-year return+40.8%731 of 3,282top 22%
3-year return+3.9%2,300 of 3,016bottom 25%
5-year return+44.5%1,161 of 2,897top 40%
10-year return+128%1,198 of 2,201bottom 47%
Volatility, 5 years31.2%838 of 2,897top 29%
Sharpe ratio, 5 years0.391,256 of 2,897top 43%
Worst decline, past 10 years−59.7%866 of 2,184top 40%

What has beaten REGN on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). REGN sits where the dashed lines cross. Anything in the green box above and to the left earned more than REGN with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.

Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to REGN; faint dots are 87 more of the 700 in the green region (the strongest, one per fund family). 3,641 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.

5.0%10.0%15.0%20.0%25.0%30.0%35.0%40.0%45.0%5.0%10.0%15.0%20.0%25.0%30.0%35.0%40.0%45.0%Volatility over 5 years (annualized)Annual return over 5 yearsMore return, less volatility than REGNTRV: +22.4% a year, volatility 22.3%BNS: +13.2% a year, volatility 20.0%ADP: +9.6% a year, volatility 23.0%CSX: +9.3% a year, volatility 23.5%IX: +18.3% a year, volatility 25.4%FMX: +14.0% a year, volatility 25.7%RS: +24.8% a year, volatility 28.1%EXPD: +11.1% a year, volatility 27.1%RNR: +20.6% a year, volatility 27.9%EWT: +19.8% a year, volatility 24.3%VLUE: +16.2% a year, volatility 18.4%MSGS: +17.5% a year, volatility 25.7%PDBC: +12.0% a year, volatility 19.3%NHC: +31.2% a year, volatility 28.6%RSPT: +16.6% a year, volatility 25.1%RY: +17.5% a year, volatility 18.2%CNXN: +16.6% a year, volatility 29.2%SRCE: +14.8% a year, volatility 27.0%XOM: +27.5% a year, volatility 26.5%AAPL: +19.1% a year, volatility 28.0%QCRH: +15.0% a year, volatility 29.1%HBT: +19.4% a year, volatility 28.7%THFF: +16.2% a year, volatility 26.2%TRST: +15.5% a year, volatility 26.8%UVSP: +11.4% a year, volatility 29.5%FCBC: +14.1% a year, volatility 28.8%CVX: +19.7% a year, volatility 25.2%FBIZ: +23.2% a year, volatility 29.4%MUFG: +33.5% a year, volatility 29.4%VTI: +11.4% a year, volatility 17.5%SHEL: +21.4% a year, volatility 24.8%VOO: +12.6% a year, volatility 16.9%WMT: +21.1% a year, volatility 22.6%BRK-A: +13.5% a year, volatility 17.2%JPM: +17.3% a year, volatility 24.3%V: +13.2% a year, volatility 22.9%E: +23.7% a year, volatility 25.6%BP: +16.8% a year, volatility 28.7%MFC: +23.3% a year, volatility 24.0%DXJ: +26.6% a year, volatility 19.1%KO: +15.2% a year, volatility 16.8%LVHI: +16.9% a year, volatility 11.1%COST: +17.4% a year, volatility 22.9%MA: +12.7% a year, volatility 23.8%QQQ: +14.2% a year, volatility 23.0%PM: +21.3% a year, volatility 23.4%MCK: +37.8% a year, volatility 25.1%VTV: +12.2% a year, volatility 13.7%XLE: +22.7% a year, volatility 25.5%RTX: +18.7% a year, volatility 24.4%GS: +19.4% a year, volatility 28.6%MS: +16.2% a year, volatility 28.9%VEA: +9.1% a year, volatility 16.9%OKE: +13.7% a year, volatility 28.0%TJX: +19.8% a year, volatility 22.3%LIN: +11.7% a year, volatility 20.9%GLD: +17.1% a year, volatility 19.0%VGT: +18.1% a year, volatility 26.1%KOF: +22.4% a year, volatility 24.7%PGR: +21.8% a year, volatility 25.7%PAA: +28.4% a year, volatility 25.6%AXP: +13.1% a year, volatility 29.2%MO: +18.3% a year, volatility 21.4%CB: +15.8% a year, volatility 20.4%PH: +26.0% a year, volatility 28.9%CM: +19.5% a year, volatility 21.6%BNY: +22.8% a year, volatility 24.4%VIG: +10.4% a year, volatility 14.1%VYM: +11.6% a year, volatility 13.8%SCHD: +10.2% a year, volatility 14.4%TT: +21.4% a year, volatility 27.7%BMO: +14.0% a year, volatility 21.4%GWW: +26.7% a year, volatility 24.9%LMT: +12.5% a year, volatility 24.4%COR: +23.6% a year, volatility 22.8%RGA: +20.5% a year, volatility 27.3%SO: +12.3% a year, volatility 18.9%PFG: +13.6% a year, volatility 26.5%CTAS: +17.1% a year, volatility 23.1%RIO: +11.9% a year, volatility 29.0%MNST: +17.4% a year, volatility 24.9%HLT: +20.7% a year, volatility 26.8%CME: +11.6% a year, volatility 20.8%VT: +10.1% a year, volatility 16.2%GD: +13.2% a year, volatility 20.8%RSG: +14.1% a year, volatility 18.6%ENB: +9.3% a year, volatility 18.9%REGN: +7.6% a year, volatility 31.2%SPY (S&P 500): +12.5% a year, volatility 17.2%AMGN: +20.1% a year, volatility 24.9%LLY: +41.2% a year, volatility 32.8%GILD: +22.8% a year, volatility 24.9%VRTX: +23.9% a year, volatility 29.1%HALO: +26.2% a year, volatility 40.4%INCY: +12.2% a year, volatility 30.1%MRK: +16.1% a year, volatility 24.8%TAK: +12.3% a year, volatility 19.4%RPRX: +13.8% a year, volatility 23.8%IHE: +12.9% a year, volatility 16.8%FBT: +10.8% a year, volatility 22.2%FTXH: +12.3% a year, volatility 16.9%CAH: +41.7% a year, volatility 24.7%MSFT: +11.9% a year, volatility 28.2%CSCO: +16.9% a year, volatility 26.1%TD: +16.5% a year, volatility 20.0%SMFG: +34.0% a year, volatility 29.4%SDCI: +21.1% a year, volatility 18.4%MFG: +33.9% a year, volatility 30.6%VXUS: +8.0% a year, volatility 16.4%REGNSPY (S&P 500)AMGNLLYGILDVRTXHALOINCYMRKRPRXIHEFBTCAHMSFTTDSMFGSDCIVXUS0.0%10.0%20.0%30.0%40.0%50.0%0.0%10.0%20.0%30.0%40.0%50.0%Volatility over 5 years (annualized)Annual return over 5 yearsMore return, less volatility than REGNTRV: +22.4% a year, volatility 22.3%BNS: +13.2% a year, volatility 20.0%ADP: +9.6% a year, volatility 23.0%CSX: +9.3% a year, volatility 23.5%IX: +18.3% a year, volatility 25.4%FMX: +14.0% a year, volatility 25.7%RS: +24.8% a year, volatility 28.1%EXPD: +11.1% a year, volatility 27.1%RNR: +20.6% a year, volatility 27.9%EWT: +19.8% a year, volatility 24.3%VLUE: +16.2% a year, volatility 18.4%MSGS: +17.5% a year, volatility 25.7%PDBC: +12.0% a year, volatility 19.3%NHC: +31.2% a year, volatility 28.6%RSPT: +16.6% a year, volatility 25.1%RY: +17.5% a year, volatility 18.2%CNXN: +16.6% a year, volatility 29.2%SRCE: +14.8% a year, volatility 27.0%XOM: +27.5% a year, volatility 26.5%AAPL: +19.1% a year, volatility 28.0%QCRH: +15.0% a year, volatility 29.1%HBT: +19.4% a year, volatility 28.7%THFF: +16.2% a year, volatility 26.2%TRST: +15.5% a year, volatility 26.8%UVSP: +11.4% a year, volatility 29.5%FCBC: +14.1% a year, volatility 28.8%CVX: +19.7% a year, volatility 25.2%FBIZ: +23.2% a year, volatility 29.4%MUFG: +33.5% a year, volatility 29.4%VTI: +11.4% a year, volatility 17.5%SHEL: +21.4% a year, volatility 24.8%VOO: +12.6% a year, volatility 16.9%WMT: +21.1% a year, volatility 22.6%BRK-A: +13.5% a year, volatility 17.2%JPM: +17.3% a year, volatility 24.3%V: +13.2% a year, volatility 22.9%E: +23.7% a year, volatility 25.6%BP: +16.8% a year, volatility 28.7%MFC: +23.3% a year, volatility 24.0%DXJ: +26.6% a year, volatility 19.1%KO: +15.2% a year, volatility 16.8%LVHI: +16.9% a year, volatility 11.1%COST: +17.4% a year, volatility 22.9%MA: +12.7% a year, volatility 23.8%QQQ: +14.2% a year, volatility 23.0%PM: +21.3% a year, volatility 23.4%MCK: +37.8% a year, volatility 25.1%VTV: +12.2% a year, volatility 13.7%XLE: +22.7% a year, volatility 25.5%RTX: +18.7% a year, volatility 24.4%GS: +19.4% a year, volatility 28.6%MS: +16.2% a year, volatility 28.9%VEA: +9.1% a year, volatility 16.9%OKE: +13.7% a year, volatility 28.0%TJX: +19.8% a year, volatility 22.3%LIN: +11.7% a year, volatility 20.9%GLD: +17.1% a year, volatility 19.0%VGT: +18.1% a year, volatility 26.1%KOF: +22.4% a year, volatility 24.7%PGR: +21.8% a year, volatility 25.7%PAA: +28.4% a year, volatility 25.6%AXP: +13.1% a year, volatility 29.2%MO: +18.3% a year, volatility 21.4%CB: +15.8% a year, volatility 20.4%PH: +26.0% a year, volatility 28.9%CM: +19.5% a year, volatility 21.6%BNY: +22.8% a year, volatility 24.4%VIG: +10.4% a year, volatility 14.1%VYM: +11.6% a year, volatility 13.8%SCHD: +10.2% a year, volatility 14.4%TT: +21.4% a year, volatility 27.7%BMO: +14.0% a year, volatility 21.4%GWW: +26.7% a year, volatility 24.9%LMT: +12.5% a year, volatility 24.4%COR: +23.6% a year, volatility 22.8%RGA: +20.5% a year, volatility 27.3%SO: +12.3% a year, volatility 18.9%PFG: +13.6% a year, volatility 26.5%CTAS: +17.1% a year, volatility 23.1%RIO: +11.9% a year, volatility 29.0%MNST: +17.4% a year, volatility 24.9%HLT: +20.7% a year, volatility 26.8%CME: +11.6% a year, volatility 20.8%VT: +10.1% a year, volatility 16.2%GD: +13.2% a year, volatility 20.8%RSG: +14.1% a year, volatility 18.6%ENB: +9.3% a year, volatility 18.9%REGN: +7.6% a year, volatility 31.2%SPY (S&P 500): +12.5% a year, volatility 17.2%AMGN: +20.1% a year, volatility 24.9%LLY: +41.2% a year, volatility 32.8%GILD: +22.8% a year, volatility 24.9%VRTX: +23.9% a year, volatility 29.1%HALO: +26.2% a year, volatility 40.4%INCY: +12.2% a year, volatility 30.1%MRK: +16.1% a year, volatility 24.8%TAK: +12.3% a year, volatility 19.4%RPRX: +13.8% a year, volatility 23.8%IHE: +12.9% a year, volatility 16.8%FBT: +10.8% a year, volatility 22.2%FTXH: +12.3% a year, volatility 16.9%CAH: +41.7% a year, volatility 24.7%MSFT: +11.9% a year, volatility 28.2%CSCO: +16.9% a year, volatility 26.1%TD: +16.5% a year, volatility 20.0%SMFG: +34.0% a year, volatility 29.4%SDCI: +21.1% a year, volatility 18.4%MFG: +33.9% a year, volatility 30.6%VXUS: +8.0% a year, volatility 16.4%REGNSPY (S&P 500)AMGNLLYGILDHALOMRKTAKCAHCSCOTDSMFGSDCIMFGVXUS
  • Popular alternatives
  • Same and neighboring categories, and shared themes
  • The whole market
  • Others in the green region

Is there a better investment than REGN?

Investments that beat REGN over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.

How this works

The table below lists investments that beat REGN over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks REGN's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than REGN follows the table.

Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than REGN's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× REGN's volatility counts as better.

These figures cover the past 5 years. Green marks a better figure than REGN's.

Screen the whole market against REGN for any period in BetterThanSPYOpen these 21 in EasyCompare
InvestmentWhy it is betterPast 5 yearsDownsideLong runFit
Annual return?higher is betterVolatility?lower is calmerSharpe?return per unit of riskWorst decline?past 10 years10Y returntotalCorr. with REGN?lower diversifies moreExpenseper year
REGNRegeneron Pharmaceuticals, Inc. · this page
+7.6%31.2%0.39−59.7%+128%1.00—
SPYState Street SPDR S&P 500 ETF · S&P 500
+12.5%17.2%0.78−33.7%+316%0.080.09%
Popular alternativesbest 6 shownThe investments people most often weigh against REGN. 10 of 22 passed at least one test.
AMGNAmgen Inc. · Biotechnology
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+20.1%24.9%0.86−24.9%+280%0.47—
LLYEli Lilly and Company · Pharmaceuticals
Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods+41.2%32.8%1.22−34.5%+1,870%0.44—
GILDGilead Sciences, Inc. · Biotechnology
Higher return, lower volatilityHigher Sharpe, smaller worst decline+22.8%24.9%0.95−30.5%+202%0.14—
VRTXVertex Pharmaceuticals Incorporated · Rare Disease Therapeutics
Higher return, lower volatilityHigher Sharpe, smaller worst decline+23.9%29.1%0.89−41.6%+580%0.25—
HALOHalozyme Therapeutics, Inc. · Biotechnology
Higher Sharpe, smaller worst declineHigher return in most periods+26.2%40.4%0.78−49.1%+1,255%0.25—
INCYIncyte Corporation · Biotechnology
Higher return, similar volatility+12.2%30.1%0.53−66.5%+32.6%0.29—
Same and neighboring categories, and shared themesbest 6 shownEverything else in Antibody Therapeutics and Biotechnology and the categories next to it (Cancer Immunotherapy, Pharmaceuticals, Life Sciences Tools, Rare Disease Therapeutics, Medical Devices), plus REGN's specific themes. 25 of 356 passed at least one test.
MRKMerck & Co., Inc. · Pharmaceuticals
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+16.1%24.8%0.73−43.4%+245%0.42—
TAKTakeda Pharmaceutical Company Limited · Specialty Pharmaceuticals
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+12.3%19.4%0.70−54.4%+33.3%0.20—
RPRXRoyalty Pharma plc · Pharmaceuticals
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+13.8%23.8%0.67−49.7%—0.16—
IHEiShares U.S. Pharmaceuticals ETF · Pharmaceuticals
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+12.9%16.8%0.81−29.6%+157%0.490.37%
FBTFirst Trust NYSE Arca Biotechnology Index Fund · Biotechnology
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+10.8%22.2%0.58−33.3%+205%0.250.55%
FTXHFirst Trust Nasdaq Pharmaceuticals ETF · Pharmaceuticals
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+12.3%16.9%0.77−32.1%+155%0.470.60%
The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,177 of 3,349 passed at least one test.
CAHCardinal Health, Inc. · Health Care Distribution
On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+41.7%24.7%1.54−46.1%+345%0.11—
MSFTMicrosoft Corporation · Software
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+11.9%28.2%0.54−37.1%+862%0.08—
CSCOCisco Systems, Inc. · Communications Equipment
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+16.9%26.1%0.73−42.0%+361%-0.08—
TDThe Toronto-Dominion Bank · Banks
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+16.5%20.0%0.87−42.0%+319%0.01—
SMFGSumitomo Mitsui Financial Group, Inc. · Banks
Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+34.0%29.4%1.15−47.6%+470%-0.05—
SDCIUSCF SummerHaven Dynamic Commodity Strategy No K-1 Fund · Broad Commodities
On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods+21.1%18.4%1.14−45.7%—0.070.80%
MFGMizuho Financial Group, Inc. · Banks
Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods+33.9%30.6%1.11−45.7%+343%-0.12—
VXUSVanguard Total International Stock ETF · International Equity
Similar return, lower volatilityHigher Sharpe, smaller worst decline+8.0%16.4%0.56−36.0%+137%0.050.05%
What these numbers mean for REGN
Annual return
REGN returned 7.6% a year over the past 5 years with dividends reinvested, against 12.5% a year for the S&P 500. At that pace, $10,000 became about $14,400. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
Volatility
REGN's volatility over the past 5 years was 31.2%, 1.8 times the S&P 500's 17.2%. Volatility measures how widely returns swing around their average: in roughly two years out of three, REGN's return lands within 31.2% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
Sharpe ratio
REGN's Sharpe ratio over the past 5 years was 0.39, against 0.78 for the S&P 500, so REGN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
Worst decline
REGN's worst fall from a peak to a low over the past 10 years was 59.7%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 59.7% fall takes a 148% gain. Guide: Market crash risk and tail risk →
Correlation
Over the past 5 years, REGN's monthly returns had a correlation of 0.08 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against REGN instead: the lower it is, the more that option would diversify a REGN holding. Guide: Correlation and diversification →
Show all 700 stocks and funds worth at least $500 million that earned more than REGN with less volatility

Out of 3,641 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.

#InvestmentFound inAnnual returnVolatilitySharpeWorst decline10Y returnCorr. with REGNExpense
1
CAHCardinal Health, Inc. · Health Care Distribution
Whole market+41.7%24.7%1.54−46.1%+345%0.11—
2
MSFTMicrosoft Corporation · Software
Whole market+11.9%28.2%0.54−37.1%+862%0.08—
3
CSCOCisco Systems, Inc. · Communications Equipment
Whole market+16.9%26.1%0.73−42.0%+361%-0.08—
4
TDThe Toronto-Dominion Bank · Banks
Whole market+16.5%20.0%0.87−42.0%+319%0.01—
5
SMFGSumitomo Mitsui Financial Group, Inc. · Banks
Whole market+34.0%29.4%1.15−47.6%+470%-0.05—
6
TRVThe Travelers Companies, Inc. · Property & Casualty Insurance
Whole market+22.4%22.3%1.02−46.3%+360%0.21—
7
BNSThe Bank of Nova Scotia · Banks
Whole market+13.2%20.0%0.73−46.9%+191%0.08—
8
ADPAutomatic Data Processing, Inc. · Business Services
Whole market+9.6%23.0%0.52−40.8%+337%0.13—
9
CSXCSX Corporation · Railroads
Whole market+9.3%23.5%0.50−40.5%+485%0.06—
10
IXORIX Corporation · Diversified Financials
Whole market+18.3%25.4%0.79−42.5%+286%0.11—
11
SDCIUSCF SummerHaven Dynamic Commodity Strategy No K-1 Fund · Broad Commodities
Whole market+21.1%18.4%1.14−45.7%—0.070.80%
12
FMXFomento Económico Mexicano, S.A.B. de C.V. · Convenience Stores
Whole market+14.0%25.7%0.64−45.5%+78.2%0.08—
13
RSReliance Steel & Aluminum Co. · Metals & Mining
Whole market+24.8%28.1%0.94−40.8%+639%0.04—
14
MRKMerck & Co., Inc. · Pharmaceuticals
Same or nearby category+16.1%24.8%0.73−43.4%+245%0.42—
15
EXPDExpeditors International of Washington, Inc. · Freight & Logistics
Whole market+11.1%27.1%0.53−35.6%+338%0.20—
16
RNRRenaissanceRe Holdings Ltd. · Insurance
Whole market+20.6%27.9%0.81−40.7%+222%0.18—
17
EWTiShares MSCI Taiwan ETF · International Equity
Whole market+19.8%24.3%0.87−38.9%+448%-0.160.59%
18
VLUEiShares MSCI USA Value Factor ETF · US Large-Cap Value
Whole market+16.2%18.4%0.91−39.5%+286%-0.020.15%
19
MSGSMadison Square Garden Sports Corp. · Entertainment
Whole market+17.5%25.7%0.76−41.6%+395%-0.05—
20
AMGNAmgen Inc. · Biotechnology
Popular alternative+20.1%24.9%0.86−24.9%+280%0.47—
21
TAKTakeda Pharmaceutical Company Limited · Specialty Pharmaceuticals
Same or nearby category+12.3%19.4%0.70−54.4%+33.3%0.20—
22
PDBCInvesco Optimum Yield Diversified Commodity Strategy No K-1 ETF · Broad Commodities
Whole market+12.0%19.3%0.69−40.7%+152%0.130.74%
23
NHCNational HealthCare Corporation · Health Care Facilities
Whole market+31.2%28.6%1.10−35.3%+385%0.22—
24
RSPTInvesco S&P 500 Equal Weight Technology ETF · Technology Equity
Whole market+16.6%25.1%0.74−33.7%+559%-0.050.40%
25
RPRXRoyalty Pharma plc · Pharmaceuticals
Same or nearby category+13.8%23.8%0.67−49.7%—0.16—
26
RYRoyal Bank of Canada · Banks
Whole market+17.5%18.2%0.98−40.0%+361%0.12—
27
CNXNPC Connection, Inc. · Technology Distribution
Whole market+16.6%29.2%0.67−41.8%+286%0.12—
28
SRCE1st Source Corporation · Regional Banks
Whole market+14.8%27.0%0.65−51.7%+221%0.13—
29
XOMExxonmobil Holdings Corporation · Integrated Oil & Gas
Whole market+27.5%26.5%1.05−61.0%+216%0.24—
30
AAPLApple Inc. · Computer Hardware
Whole market+19.1%28.0%0.77−38.5%+1,194%0.20—
31
QCRHQCR Holdings, Inc. · Regional Banks
Whole market+15.0%29.1%0.63−53.0%+243%0.10—
32
IHEiShares U.S. Pharmaceuticals ETF · Pharmaceuticals
Same or nearby category+12.9%16.8%0.81−29.6%+157%0.490.37%
33
HBTHBT Financial, Inc. · Regional Banks
Whole market+19.4%28.7%0.76−54.0%—0.12—
34
FBTFirst Trust NYSE Arca Biotechnology Index Fund · Biotechnology
Same or nearby category+10.8%22.2%0.58−33.3%+205%0.250.55%
35
FTXHFirst Trust Nasdaq Pharmaceuticals ETF · Pharmaceuticals
Same or nearby category+12.3%16.9%0.77−32.1%+155%0.470.60%
36
THFFFirst Financial Corporation · Regional Banks
Whole market+16.2%26.2%0.71−42.8%+164%0.03—
37
TRSTTrustCo Bank Corp NY · Regional Banks
Whole market+15.5%26.8%0.67−49.5%+127%0.16—
38
UVSPUnivest Financial Corporation · Regional Banks
Whole market+11.4%29.5%0.51−53.4%+144%0.10—
39
FCBCFirst Community Bankshares, Inc. · Regional Banks
Whole market+14.1%28.8%0.60−49.5%+212%0.05—
40
CVXChevron Corporation · Integrated Oil & Gas
Whole market+19.7%25.2%0.84−55.8%+243%0.24—
41
FBIZFirst Business Financial Services, Inc. · Regional Banks
Whole market+23.2%29.4%0.86−50.2%+315%0.13—
42
MUFGMitsubishi UFJ Financial Group, Inc. · Banks
Whole market+33.5%29.4%1.14−54.9%+485%-0.15—
43
VTIVanguard Morningstar Total Stock Market ETF · US Total Market
Whole market+11.4%17.5%0.71−35.0%+298%0.070.03%
44
SHELShell plc · Integrated Oil & Gas
Whole market+21.4%24.8%0.91−67.2%+236%0.23—
45
VOOVanguard S&P 500 ETF · US Large-Cap Equity
Whole market+12.6%16.9%0.79−34.0%+319%0.080.03%
46
WMTWalmart Inc. · Discount Retail
Whole market+21.1%22.6%0.97−25.7%+521%0.17—
47
BRK-ABerkshire Hathaway Inc. · Insurance
Whole market+13.5%17.2%0.83−30.4%+281%0.35—
48
JPMJPMorgan Chase & Co. · Banks
Whole market+17.3%24.3%0.78−43.6%+534%0.12—
49
VVisa Inc. · Payment Processing
Whole market+13.2%22.9%0.66−36.4%+435%0.04—
50
EEni S.p.A. · Integrated Oil & Gas
Whole market+23.7%25.6%0.96−61.4%+283%0.26—
51
BPBP p.l.c. · Integrated Oil & Gas
Whole market+16.8%28.7%0.69−63.9%+145%0.26—
52
MFCManulife Financial Corporation · Life Insurance
Whole market+23.3%24.0%1.00−57.5%+386%0.15—
53
DXJWisdomTree Japan Hedged Equity Fund · Japan Equity
Whole market+26.6%19.1%1.34−39.1%+415%0.050.48%
54
KOThe Coca-Cola Company · Nonalcoholic Beverages
Whole market+15.2%16.8%0.93−37.0%+205%0.28—
55
LVHIFranklin International Low Volatility High Dividend Index ETF · International Dividend Equity
Whole market+16.9%11.1%1.48−32.4%+194%0.240.40%
56
COSTCostco Wholesale Corporation · Discount Retail
Whole market+17.4%22.9%0.82−31.4%+692%0.16—
57
MAMastercard Incorporated · Payment Processing
Whole market+12.7%23.8%0.62−41.0%+551%0.11—
58
QQQInvesco QQQ Trust, Series 1 · US Large-Cap Growth
Whole market+14.2%23.0%0.69−35.1%+531%-0.040.18%
59
PMPhilip Morris International Inc. · Tobacco
Whole market+21.3%23.4%0.94−42.9%+240%-0.10—
60
MCKMcKesson Corporation · Health Care Distribution
Whole market+37.8%25.1%1.41−38.1%+582%0.17—
61
VTVVanguard Morningstar Value ETF · US Large-Cap Value
Whole market+12.2%13.7%0.91−36.8%+237%0.170.03%
62
XLEState Street Energy Select Sector SPDR ETF · Energy Equity
Whole market+22.7%25.5%0.94−66.8%+190%0.240.08%
63
RTXRTX Corporation · Aerospace & Defense
Whole market+18.7%24.4%0.83−52.0%+319%0.10—
64
GSThe Goldman Sachs Group, Inc. · Capital Markets
Whole market+19.4%28.6%0.77−48.8%+524%-0.01—
65
MSMorgan Stanley · Capital Markets
Whole market+16.2%28.9%0.67−51.3%+630%-0.06—
66
VEAVanguard FTSE Developed Markets ETF · Developed International Equity
Whole market+9.1%16.9%0.60−35.8%+152%0.100.03%
67
OKEONEOK, Inc. · Oil & Gas Midstream
Whole market+13.7%28.0%0.60−80.2%+241%0.17—
68
TJXThe TJX Companies, Inc. · Apparel Retail
Whole market+19.8%22.3%0.93−42.5%+357%0.24—
69
LINLinde plc · Chemicals
Whole market+11.7%20.9%0.64−32.6%+404%0.07—
70
GLDSPDR Gold Shares · Gold
Whole market+17.1%19.0%0.93−26.4%+206%0.020.40%
71
VGTVanguard Information Technology ETF · Technology Equity
Whole market+18.1%26.1%0.77−35.1%+753%-0.060.09%
72
KOFCoca-Cola FEMSA, S.A.B. de C.V. · Food & Beverages
Whole market+22.4%24.7%0.95−55.1%+119%0.09—
73
PGRThe Progressive Corporation · Property & Casualty Insurance
Whole market+21.8%25.7%0.90−30.3%+849%0.12—
74
PAAPlains All American Pipeline, L.P. · Oil & Gas Midstream
Whole market+28.4%25.6%1.11−87.9%+66.5%0.17—
75
AXPAmerican Express Company · Consumer Finance
Whole market+13.1%29.2%0.57−49.6%+455%0.04—
76
MOAltria Group, Inc. · Tobacco
Whole market+18.3%21.4%0.90−53.7%+133%-0.04—
77
CBChubb Limited · Property & Casualty Insurance
Whole market+15.8%20.4%0.82−42.6%+256%0.25—
78
PHParker-Hannifin Corporation · Industrial Machinery
Whole market+26.0%28.9%0.95−54.7%+755%0.12—
79
CMCanadian Imperial Bank of Commerce · Banks
Whole market+19.5%21.6%0.94−47.3%+409%0.09—
80
BNYBank of New York Mellon Corp · Banks
Whole market+22.8%24.4%0.97−50.5%+332%0.06—
81
VIGVanguard Dividend Appreciation ETF · Dividend Growth
Whole market+10.4%14.1%0.77−31.7%+258%0.170.04%
82
VYMVanguard High Dividend Yield ETF · High Dividend Yield
Whole market+11.6%13.8%0.87−35.2%+209%0.180.04%
83
SCHDSchwab U.S. Dividend Equity ETF · US Dividend Equity
Whole market+10.2%14.4%0.75−33.4%+256%0.240.06%
84
TTTrane Technologies plc · Building Products
Whole market+21.4%27.7%0.84−40.5%+927%-0.01—
85
BMOBank of Montreal · Banks
Whole market+14.0%21.4%0.72−51.0%+304%-0.03—
86
GWWW.W. Grainger, Inc. · Industrial Distribution
Whole market+26.7%24.9%1.08−41.6%+670%-0.03—
87
LMTLockheed Martin Corporation · Aerospace & Defense
Whole market+12.5%24.4%0.61−36.7%+226%0.08—
88
CORCencora, Inc. · Health Care Distribution
Whole market+23.6%22.8%1.05−32.4%+403%0.22—
89
RGAReinsurance Group of America, Incorporated · Insurance
Whole market+20.5%27.3%0.82−65.8%+206%0.16—
90
SOThe Southern Company · Electric Utilities
Whole market+12.3%18.9%0.71−38.4%+178%0.02—
91
PFGPrincipal Financial Group, Inc. · Life Insurance
Whole market+13.6%26.5%0.62−64.7%+201%0.15—
92
CTASCintas Corporation · Business Services
Whole market+17.1%23.1%0.80−48.4%+834%0.19—
93
RIORio Tinto Group · Metals & Mining
Whole market+11.9%29.0%0.54−37.5%+427%0.12—
94
MNSTMonster Beverage Corporation · Nonalcoholic Beverages
Whole market+17.4%24.9%0.77−30.4%+278%-0.11—
95
HLTHilton Worldwide Holdings Inc. · Hotels & Resorts
Whole market+20.7%26.8%0.84−50.8%+693%0.16—
96
CMECME Group Inc. · Capital Markets
Whole market+11.6%20.8%0.63−37.4%+334%0.15—
97
VTVanguard Total World Stock ETF · Global Equity
Whole market+10.1%16.2%0.68−34.2%+220%0.070.06%
98
GDGeneral Dynamics Corporation · Aerospace & Defense
Whole market+13.2%20.8%0.70−51.6%+188%0.17—
99
RSGRepublic Services, Inc. · Waste Management
Whole market+14.1%18.6%0.80−34.0%+461%0.07—
100
ENBEnbridge Inc. · Oil & Gas Midstream
Whole market+9.3%18.9%0.57−44.1%+106%0.10—

REGN against its popular alternatives

The investments people most often weigh against REGN, compared period by period and year by year.

How do REGN's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at REGN, which divides the map into what did better or worse on each measure.

Green points earned more than REGN with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.

10.0%20.0%30.0%40.0%50.0%60.0%70.0%80.0%−30.0%−20.0%−10.0%0.0%10.0%20.0%30.0%40.0%50.0%Volatility over 5 years (annualized)Annual return over 5 yearsHigher return, lower volatilityLower return, higher volatilityREGN: 7.6% a year, volatility 31.2%SPY (S&P 500): 12.5% a year, volatility 17.2%AMGN: 20.1% a year, volatility 24.9%VRTX: 23.9% a year, volatility 29.1%GILD: 22.8% a year, volatility 24.9%INCY: 12.2% a year, volatility 30.1%ALNY: 2.7% a year, volatility 50.9%NBIX: 6.7% a year, volatility 33.2%BIIB: −0.8% a year, volatility 34.8%IONS: 7.6% a year, volatility 43.9%BMRN: −5.1% a year, volatility 33.0%SRPT: −25.7% a year, volatility 70.3%RARE: −27.2% a year, volatility 58.4%BNTX: −20.1% a year, volatility 52.5%HALO: 26.2% a year, volatility 40.4%LLY: 41.2% a year, volatility 32.8%EXEL: 25.0% a year, volatility 35.8%TMO: 2.3% a year, volatility 27.8%DHR: −3.2% a year, volatility 29.2%PCVX: 22.6% a year, volatility 64.1%UTHR: 25.1% a year, volatility 35.2%PTCT: 11.9% a year, volatility 55.0%ARGX: 24.5% a year, volatility 39.9%SNY: 0.5% a year, volatility 25.4%REGNSPY (S&P 500)AMGNVRTXGILDINCYALNYBIIBIONSBMRNSRPTRAREBNTXHALOLLYEXELTMODHRPCVXPTCTSNY0.0%20.0%40.0%60.0%80.0%−40.0%−20.0%0.0%20.0%40.0%60.0%Volatility over 5 years (annualized)Annual return over 5 yearsHigher return, lower volatilityLower return, higher volatilityREGN: 7.6% a year, volatility 31.2%SPY (S&P 500): 12.5% a year, volatility 17.2%AMGN: 20.1% a year, volatility 24.9%VRTX: 23.9% a year, volatility 29.1%GILD: 22.8% a year, volatility 24.9%INCY: 12.2% a year, volatility 30.1%ALNY: 2.7% a year, volatility 50.9%NBIX: 6.7% a year, volatility 33.2%BIIB: −0.8% a year, volatility 34.8%IONS: 7.6% a year, volatility 43.9%BMRN: −5.1% a year, volatility 33.0%SRPT: −25.7% a year, volatility 70.3%RARE: −27.2% a year, volatility 58.4%BNTX: −20.1% a year, volatility 52.5%HALO: 26.2% a year, volatility 40.4%LLY: 41.2% a year, volatility 32.8%EXEL: 25.0% a year, volatility 35.8%TMO: 2.3% a year, volatility 27.8%DHR: −3.2% a year, volatility 29.2%PCVX: 22.6% a year, volatility 64.1%UTHR: 25.1% a year, volatility 35.2%PTCT: 11.9% a year, volatility 55.0%ARGX: 24.5% a year, volatility 39.9%SNY: 0.5% a year, volatility 25.4%REGNSPY (S&P 500)AMGNGILDALNYNBIXBIIBIONSBMRNSRPTRAREBNTXHALOLLYEXELTMODHRPCVXPTCT
All figures
InvestmentAnnual returnVolatility
LLY Eli Lilly and Company+41.2%32.8%
HALO Halozyme Therapeutics, Inc.+26.2%40.4%
UTHR United Therapeutics Corporation+25.1%35.2%
EXEL Exelixis, Inc.+25.0%35.8%
ARGX argenx SE+24.5%39.9%
VRTX Vertex Pharmaceuticals Incorporated+23.9%29.1%
GILD Gilead Sciences, Inc.+22.8%24.9%
PCVX Vaxcyte, Inc.+22.6%64.1%
AMGN Amgen Inc.+20.1%24.9%
SPY S&P 500State Street SPDR S&P 500 ETF+12.5%17.2%
INCY Incyte Corporation+12.2%30.1%
PTCT PTC Therapeutics, Inc.+11.9%55.0%
REGN This pageRegeneron Pharmaceuticals, Inc.+7.6%31.2%
IONS Ionis Pharmaceuticals, Inc.+7.6%43.9%
NBIX Neurocrine Biosciences, Inc.+6.7%33.2%
ALNY Alnylam Pharmaceuticals, Inc.+2.7%50.9%
TMO Thermo Fisher Scientific Inc.+2.3%27.8%
SNY Sanofi+0.5%25.4%
BIIB Biogen Inc.−0.8%34.8%
DHR Danaher Corporation−3.2%29.2%
BMRN BioMarin Pharmaceutical Inc.−5.1%33.0%
BNTX BioNTech SE−20.1%52.5%
SRPT Sarepta Therapeutics, Inc.−25.7%70.3%
RARE Ultragenyx Pharmaceutical Inc.−27.2%58.4%
Open these 24 in EasyCompare

Has REGN consistently beaten its popular alternatives?

This section compares REGN with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than REGN helps separate lasting outperformance from a single strong stretch.

A green cell means the alternative earned more than REGN over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.

InvestmentPeriods outperformed Short termLong termRisk · 5 yearsFund
1M3M6MYTD1Y3Y5Y10YVolatilitylower is calmerSharpehigher is betterWorst declinepast 10 yearsExpenseAssetsOverlapsame sectors
REGN Regeneron Pharmaceuticals, Inc. (this page)—+1.9%+25.9%+10.0%+5.9%+40.8%+3.9%+44.5%+128%31.2%0.39−59.7%—$84B—
HALO QualifiedHalozyme Therapeutics, Inc.5/5 short3/3 longAll-weather+8.2%+60.0%+82.1%+77.1%+89.4%+258%+220%+1,255%40.4%0.78−49.1%—$14B—
LLY QualifiedEli Lilly and Company4/5 short3/3 longAll-weather+11.7%+12.5%+42.3%+21.5%+61.9%+131%+461%+1,870%32.8%1.22−34.5%—$1.2T—
EXEL QualifiedExelixis, Inc.4/5 short3/3 longAll-weather+12.3%+18.8%+39.4%+49.9%+81.0%+239%+205%+478%35.8%0.81−57.2%—$16B—
AMGN QualifiedAmgen Inc.4/5 short3/3 longAll-weather+9.0%+22.9%+31.0%+39.3%+55.3%+79.2%+150%+280%24.9%0.86−24.9%—$242B—
VRTX QualifiedVertex Pharmaceuticals Incorporated3/5 short3/3 long+3.9%+13.2%+22.3%+18.4%+25.5%+45.6%+192%+580%29.1%0.89−41.6%—$136B—
GILD QualifiedGilead Sciences, Inc.3/5 short3/3 long+3.0%+21.3%+19.7%+31.6%+32.6%+123%+179%+202%24.9%0.95−30.5%—$195B—
TMO QualifiedThermo Fisher Scientific Inc.4/5 short2/3 long+2.7%+28.6%+31.9%+14.5%+19.7%+47.9%+12.1%+355%27.8%0.22−40.9%—$250B—
DHR QualifiedDanaher Corporation3/5 short2/3 long+4.1%+28.5%+25.3%+0.3%+6.1%+14.6%−15.2%+240%29.2%0.03−43.8%—$161B—
PCVX QualifiedVaxcyte, Inc.3/5 short2/3 long+6.5%+12.2%+3.4%+35.3%+47.8%+34.0%+177%—64.1%0.63−76.2%—$9.9B—
UTHR BiotechnologyUnited Therapeutics Corporation2/5 short3/3 long+17.5%+11.0%+1.8%+17.7%+38.7%+161%+206%+423%35.2%0.81−55.6%—$25B—
PTCT BiotechnologyPTC Therapeutics, Inc.0/5 short3/3 long−4.4%−19.6%−11.0%−17.9%−5.2%+177%+75.2%+841%55.0%0.48−73.8%—$5.3B—
INCY BiotechnologyIncyte Corporation2/5 short2/3 long−7.9%+1.0%+20.9%+15.3%+32.8%+112%+77.7%+32.6%30.1%0.53−66.5%—$24B—
ALNY BiotechnologyAlnylam Pharmaceuticals, Inc.0/5 short2/3 long−9.7%−14.9%−26.8%−43.2%−51.1%+40.3%+14.4%+511%50.9%0.30−58.2%—$30B—
NBIX BiotechnologyNeurocrine Biosciences, Inc.0/5 short2/3 long+0.7%−17.0%+9.2%+1.9%+1.3%+32.8%+38.4%+218%33.2%0.37−46.4%—$15B—
ARGX Biotechnologyargenx SE0/5 short2/3 long−9.1%+2.8%+10.4%+4.3%+7.6%+84.2%+199%—39.9%0.75−38.2%—$55B—
BIIB Drug Manufacturers - GeneralBiogen Inc.5/5 short0/3 long+12.6%+28.4%+33.6%+42.8%+71.8%+0.2%−4.1%−12.7%34.8%0.14−72.7%—$38B—
SNY Drug Manufacturers - GeneralSanofi0/5 short0/3 long−1.3%−4.2%−7.0%−9.5%−12.7%−8.8%+2.6%+65.1%25.4%0.15−33.5%—$101B—
IONS BiotechnologyIonis Pharmaceuticals, Inc.0/5 short0/3 long−4.0%−18.7%−41.3%−44.9%−38.6%−4.1%+44.3%+58.8%43.9%0.39−70.4%—$7.3B—
BMRN BiotechnologyBioMarin Pharmaceutical Inc.0/5 short0/3 long−10.6%−3.0%+4.6%−4.7%+6.1%−31.6%−23.2%−31.1%33.0%0.00−62.1%—$11B—
SRPT BiotechnologySarepta Therapeutics, Inc.0/5 short0/3 long−12.6%+14.9%−11.9%−14.7%−19.1%−83.7%−77.3%−61.3%70.3%-0.05−93.3%—$1.9B—
RARE BiotechnologyUltragenyx Pharmaceutical Inc.0/5 short0/3 long+2.1%−42.3%−35.2%−32.4%−51.9%−50.2%−79.6%−75.8%58.4%-0.23−92.7%—$1.6B—
BNTX BiotechnologyBioNTech SE0/5 short0/3 long−11.1%−2.4%−17.4%−7.3%−15.6%−3.1%−67.4%—52.5%-0.17−82.3%—$23B—
Open these 23 in EasyCompare

How did REGN do year by year?

This table shows each investment's total return in every full calendar year since 1997, along with where REGN ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with REGN and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.

Newest year first. Green marks a year in which the fund came out ahead of REGN; gray means the two finished within a fraction of a point. The rank row places REGN among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.

InvestmentYears ahead of REGN20252024202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997
REGN This pageRegeneron Pharmaceuticals, Inc.—+9.0%−18.9%+21.7%+14.2%+30.7%+28.7%+0.5%−0.7%+2.4%−32.4%+32.3%+49.0%+60.9%+209%+68.8%+35.8%+31.7%−24.0%+20.3%+26.2%+72.7%−37.4%−20.6%−34.3%−20.2%+177%+72.8%−13.8%−46.9%
Rank among alternativesTop quarter in 7 of 2915 of 2320 of 236 of 2314 of 236 of 2310 of 2216 of 2111 of 2118 of 2015 of 207 of 206 of 1910 of 182 of 181 of 185 of 188 of 189 of 189 of 188 of 183 of 1815 of 1615 of 168 of 1512 of 152 of 144 of 129 of 1211 of 11
SPY S&P 500State Street SPDR S&P 500 ETF12 of 29+17.7%+24.9%+26.2%−18.2%+28.7%+18.3%+31.2%−4.6%+21.7%+12.0%+1.2%+13.5%+32.3%+16.0%+1.9%+15.1%+26.4%−36.8%+5.1%+15.9%+4.8%+10.7%+28.2%−21.6%−11.7%−9.8%+20.4%+28.7%+33.5%
HALO Halozyme Therapeutics, Inc.10 of 21+40.8%+29.4%−35.0%+41.5%−5.9%+141%+21.2%−27.8%+105%−43.0%+79.6%−35.6%+123%−29.4%+20.1%+34.9%+4.8%−21.2%−11.7%+342%−17.3%————————
LLY Eli Lilly and Company17 of 29+40.3%+33.3%+60.9%+34.3%+66.1%+31.0%+16.2%+40.5%+17.8%−10.4%+25.4%+39.8%+7.3%+24.2%+25.2%+3.6%−6.2%−21.3%+5.7%−5.2%+2.6%−17.6%+13.1%−17.6%−14.4%+41.9%−24.3%+29.1%+93.6%
EXEL Exelixis, Inc.10 of 25+31.6%+38.8%+49.6%−12.3%−8.9%+13.9%−10.4%−35.3%+104%+164%+292%−76.5%+34.1%−3.6%−42.3%+11.4%+46.8%−41.8%−4.1%−4.5%−0.8%+34.8%−11.9%−51.9%+13.6%————
AMGN Amgen Inc.15 of 29+29.7%−6.8%+13.5%+20.4%+0.9%−2.0%+27.6%+15.2%+22.3%−7.6%+4.0%+42.3%+34.8%+36.8%+18.2%−3.0%−2.0%+24.3%−32.0%−13.4%+22.9%+3.8%+27.8%−14.4%−11.7%+6.5%+130%+93.3%−0.4%
VRTX Vertex Pharmaceuticals Incorporated17 of 29+12.6%−1.0%+40.9%+31.5%−7.1%+7.9%+32.1%+10.6%+103%−41.4%+5.9%+59.9%+77.3%+26.2%−5.2%−18.3%+41.0%+30.8%−37.9%+35.2%+162%+2.1%−34.7%−35.5%−65.6%+309%+17.6%−9.8%−18.0%
GILD Gilead Sciences, Inc.15 of 29+36.6%+18.7%−2.0%+23.6%+29.9%−6.7%+7.9%−9.9%+3.0%−27.6%+8.6%+25.5%+105%+79.5%+12.9%−16.3%−15.4%+11.2%+41.7%+23.4%+50.2%+20.1%+71.4%+3.6%+58.2%+53.9%+31.7%+6.7%+53.6%
TMO Thermo Fisher Scientific Inc.17 of 29+11.8%−1.7%−3.4%−17.3%+43.5%+43.7%+45.6%+18.2%+35.0%−0.1%+13.8%+13.1%+75.8%+43.2%−18.8%+16.1%+40.0%−40.9%+27.4%+50.3%−0.2%+19.8%+25.3%−15.7%+5.6%+98.2%−11.4%−61.5%+6.7%
DHR Danaher Corporation16 of 29+0.4%−0.4%−1.2%−19.0%+48.6%+45.4%+49.5%+11.8%+20.0%+73.2%+9.3%+11.6%+38.3%+19.1%−0.1%+25.7%+33.0%−35.4%+21.3%+30.1%−2.7%+25.3%+39.7%+9.1%−11.7%+41.5%−11.0%+72.4%+35.2%
PCVX Vaxcyte, Inc.3 of 5−43.6%+30.3%+31.0%+102%−10.5%————————————————————————
UTHR United Therapeutics Corporation13 of 26+38.1%+60.5%−20.9%+28.7%+42.4%+72.3%−19.1%−26.4%+3.1%−8.4%+20.9%+14.5%+112%+13.1%−25.3%+20.1%+68.3%−35.9%+79.7%−21.3%+53.1%+96.7%+37.5%+60.3%−29.4%−67.9%———
PTCT PTC Therapeutics, Inc.6 of 12+68.3%+63.8%−27.8%−4.2%−34.7%+27.1%+40.0%+106%+52.9%−66.3%−37.4%+205%—————————————————
INCY Incyte Corporation12 of 29+43.0%+10.0%−21.8%+9.4%−15.6%−0.4%+37.3%−32.9%−5.5%−7.5%+48.3%+44.4%+205%+10.7%−9.4%+81.8%+140%−62.3%+72.1%+9.4%−46.6%+46.1%+50.0%−76.5%−21.9%−17.1%+60.5%−16.9%+74.7%
ALNY Alnylam Pharmaceuticals, Inc.11 of 21+69.0%+22.9%−19.5%+40.1%+30.5%+12.8%+58.0%−42.6%+239%−60.2%−2.9%+50.8%+252%+124%−17.3%−44.0%−28.7%−15.0%+35.9%+60.2%+78.8%————————
NBIX Neurocrine Biosciences, Inc.14 of 29+3.9%+3.6%+10.3%+40.2%−11.1%−10.8%+50.5%−8.0%+100%−31.6%+153%+139%+24.9%−12.0%+11.3%+181%−15.0%−29.5%−56.4%−83.4%+27.2%−9.6%+19.4%−11.0%+54.9%+33.9%+260%−12.7%−21.2%
ARGX argenx SE5 of 8+36.7%+61.7%+0.4%+8.2%+19.1%+83.2%+67.1%+52.1%—————————————————————
BIIB Biogen Inc.12 of 29+15.1%−40.9%−6.6%+15.4%−2.0%−17.5%−1.4%−5.5%+12.3%−7.4%−9.8%+21.4%+91.0%+33.0%+64.1%+25.3%+12.3%−16.3%+15.7%+8.6%−32.0%+81.5%+10.6%−51.9%+9.1%+93.0%+318%+36.6%+44.7%
SNY Sanofi7 of 23+4.9%+1.1%+6.5%+0.5%+7.0%+0.4%+20.5%+6.0%+9.9%−1.2%−3.4%−11.9%+17.1%+36.0%+18.8%−13.4%+28.7%−26.5%+1.0%+7.2%+11.6%+8.2%+26.2%——————
IONS Ionis Pharmaceuticals, Inc.17 of 29+126%−30.9%+33.9%+24.1%−46.2%−6.4%+11.8%+7.5%+5.2%−22.8%+0.3%+55.0%+282%+44.8%−28.7%−8.9%−21.6%−10.0%+41.6%+112%−11.2%−9.2%−1.4%−70.3%+109%+70.1%−51.7%+5.1%−31.6%
BMRN BioMarin Pharmaceutical Inc.9 of 26−9.6%−31.8%−6.8%+17.1%+0.8%+3.7%−0.7%−4.5%+7.6%−20.9%+15.9%+28.5%+43.0%+43.1%+27.7%+43.2%+5.7%−49.7%+116%+52.0%+68.7%−17.6%+10.1%−47.5%+38.7%−17.5%———
SRPT Sarepta Therapeutics, Inc.13 of 28−82.3%+26.1%−25.6%+43.9%−47.2%+32.1%+18.2%+96.1%+103%−28.9%+167%−29.0%−21.1%+473%−64.6%+45.2%+121%−53.2%−55.7%−7.8%+46.8%−42.3%−18.6%−54.2%+130%−12.7%+36.0%−41.3%—
RARE Ultragenyx Pharmaceutical Inc.3 of 11−45.3%−12.0%+3.2%−44.9%−39.3%+224%−1.8%−6.3%−34.0%−37.3%+156%——————————————————
BNTX BioNTech SE3 of 6−16.4%+8.0%−29.7%−41.0%+216%+141%———————————————————————
Open these 24 in EasyCompare

Risk and diversification

How REGN has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

What were REGN's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high. This section presents REGN's five deepest drawdowns since it began trading in 1991, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.

Green means REGN fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.

DuringREGN fellS&P 500, same datesPeakLowTime to the lowBack at the peakTime to recover
Dot-com bust−91.8%−8.9%Feb 2000Apr 20055.2 yearsApr 20116 years
No named crash−86.7%—Feb 1992Dec 19942.8 yearsOct 199622 months
No named crash−77.4%+96.7%Oct 1996Apr 19992.5 yearsFeb 200010 months
No named crash−59.7%+6.6%Aug 2024Jun 202510 monthsNot yet—
2015 China and oil sell-off−53.8%+53.0%Aug 2015Sep 20194.1 yearsMay 20208 months

How did REGN do in stock market crashes?

This section measures how far REGN, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.

Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than REGN.

InvestmentHeld up better2023 regional bank crisisMar 20232022 bear marketJan 2022Covid crashFeb 2020Late-2018 sell-offSep 2018February 2018 volatility shockFeb 20182015 China and oil sell-offAug 20152011 euro debt crisisJul 20112010 flash crashMay 20102008 financial crisisOct 2007Dot-com bustMar 2000
REGN This pageRegeneron Pharmaceuticals, Inc.—−0.2%−25.8%−12.7%−17.3%−7.3%−37.7%−23.2%−7.2%−49.9%−71.6%
SPY S&P 500State Street SPDR S&P 500 ETF6 of 10−3.4%−24.5%−33.7%−19.3%−6.5%−12.8%−17.9%−1.5%−55.2%−47.5%
HALO Halozyme Therapeutics, Inc.1 of 9−2.6%−25.6%−36.3%−28.6%−7.1%−66.0%−21.1%−7.6%−70.6%—
LLY Eli Lilly and Company6 of 10−0.6%−11.7%−16.9%−10.2%−8.6%−19.6%−10.9%0.0%−50.0%−54.3%
EXEL Exelixis, Inc.2 of 90.0%−35.4%−33.7%−24.9%−8.7%−36.4%−43.7%−5.4%−80.0%—
AMGN Amgen Inc.7 of 10−1.2%−11.9%−18.3%−14.3%−7.4%−22.1%−12.6%−0.5%−31.3%−60.2%
VRTX Vertex Pharmaceuticals Incorporated2 of 100.0%−19.2%−19.4%−21.2%−8.8%−43.7%−23.9%−2.7%−59.9%−86.7%
GILD Gilead Sciences, Inc.7 of 10−1.6%−20.0%−13.7%−22.7%−5.5%−28.7%−18.2%−2.1%−34.3%−53.6%
TMO Thermo Fisher Scientific Inc.4 of 10−2.4%−19.8%−24.8%−17.2%−8.7%−14.7%−24.4%−3.6%−53.9%−41.8%
DHR Danaher Corporation7 of 10−3.2%−22.8%−25.9%−13.4%−9.8%−14.0%−21.8%−0.6%−45.7%−33.7%
PCVX Vaxcyte, Inc.0 of 2−8.2%−33.5%————————
UTHR United Therapeutics Corporation4 of 10−1.8%−22.3%−31.2%−21.2%−5.3%−31.3%−35.1%−3.5%−57.8%−93.2%
PTCT PTC Therapeutics, Inc.0 of 6−8.2%−43.4%−45.5%−36.8%−7.4%−47.7%————
INCY Incyte Corporation4 of 10−2.4%−20.4%−23.7%−16.4%−4.8%−50.2%−32.9%−4.5%−83.5%−97.1%
ALNY Alnylam Pharmaceuticals, Inc.1 of 9−4.1%−28.9%−30.0%−33.7%−6.9%−48.9%−39.3%−1.5%−58.6%—
NBIX Neurocrine Biosciences, Inc.3 of 10−3.5%−24.3%−27.9%−45.1%−5.7%−44.1%−32.8%−7.1%−83.0%−65.8%
ARGX argenx SE1 of 50.0%−26.0%−32.8%−19.8%−1.2%—————
BIIB Biogen Inc.5 of 10−2.5%−22.4%−21.2%−21.7%−9.3%−24.6%−19.4%−0.6%−52.7%−59.8%
SNY Sanofi5 of 9−0.5%−33.5%−25.2%−9.0%−9.8%−30.2%−20.7%−2.8%−46.6%—
IONS Ionis Pharmaceuticals, Inc.2 of 10−5.8%−26.3%−32.6%−18.1%−8.5%−48.8%−25.7%−2.1%−45.6%−74.6%
BMRN BioMarin Pharmaceutical Inc.2 of 10−4.5%−22.9%−26.3%−24.4%−11.6%−53.6%−23.1%−4.1%−74.9%−89.7%
SRPT Sarepta Therapeutics, Inc.1 of 10−6.7%−29.7%−33.6%−39.7%−12.6%−74.3%−39.5%−5.0%−84.4%−87.3%
RARE Ultragenyx Pharmaceutical Inc.0 of 6−8.8%−56.5%−45.1%−56.9%−9.6%−61.4%————
BNTX BioNTech SE0 of 3−1.2%−45.7%−49.5%———————
Open these 24 in EasyCompare

How closely does REGN move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares REGN with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.

Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than REGN's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.

InvestmentUpside captureDownside captureCapture ratioBeta
REGN This pageRegeneron Pharmaceuticals, Inc.55%66%0.840.19
LLY Eli Lilly and Company101%6%15.730.37
VRTX Vertex Pharmaceuticals Incorporated87%50%1.750.46
EXEL Exelixis, Inc.74%43%1.720.73
UTHR United Therapeutics Corporation75%45%1.660.52
GILD Gilead Sciences, Inc.52%36%1.440.35
HALO Halozyme Therapeutics, Inc.129%102%1.271.15
AMGN Amgen Inc.74%64%1.160.54
NBIX Neurocrine Biosciences, Inc.69%66%1.040.56
DHR Danaher Corporation84%84%1.010.75
TMO Thermo Fisher Scientific Inc.104%104%1.000.81
ALNY Alnylam Pharmaceuticals, Inc.92%93%0.990.73
PTCT PTC Therapeutics, Inc.112%115%0.970.85
SNY Sanofi53%74%0.720.46
INCY Incyte Corporation52%87%0.600.77
IONS Ionis Pharmaceuticals, Inc.71%125%0.560.74
BIIB Biogen Inc.35%91%0.380.28
SRPT Sarepta Therapeutics, Inc.71%217%0.330.89
BMRN BioMarin Pharmaceutical Inc.20%70%0.290.38
RARE Ultragenyx Pharmaceutical Inc.19%142%0.131.07
Open these 20 in EasyCompare

What diversifies REGN?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with REGN's. Because such investments tend not to fall at the same time, pairing REGN with them can reduce a portfolio's overall swings.

Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which REGN lost money. The last two columns show a portfolio that is 80% REGN and 20% the other investment, rebalanced monthly.

ETFs

InvestmentCorrelation5Y returnSharpe202420182016200820042003200220011998199780/20 mix volatility80/20 mix annual return
REGN Regeneron Pharmaceuticals, Inc. (this page)1.00+44.5%0.39−18.9%−0.7%−32.4%−24.0%−37.4%−20.6%−34.3%−20.2%−13.8%−46.9%29.7%+4.8%
LVHI InternationalFranklin International Low Volatility High Dividend Index ETF0.24+119%1.48+15.9%−5.2%————————24.3%+7.8%
DXJ InternationalWisdomTree Japan Hedged Equity Fund0.05+225%1.34+29.8%−19.8%+1.1%−20.8%——————24.0%+9.8%
EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund0.10+103%1.06+33.4%−8.7%+29.8%———————24.2%+7.7%
HDV Dividend & IncomeiShares Core High Dividend ETF0.26+86.8%1.03+14.2%−3.0%+15.8%———————24.6%+6.9%
DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF0.13+83.6%0.95+13.4%−9.5%+6.3%———————24.1%+7.3%
SMH TechnologyVanEck Semiconductor ETF-0.09+304%0.94+39.1%−9.1%+35.6%−44.7%−19.3%+87.3%−47.0%−14.6%——24.1%+12.6%
XLE EnergyState Street Energy Select Sector SPDR ETF0.24+178%0.94+5.6%−18.2%+28.0%−39.0%+33.8%+25.9%−14.8%−18.2%——25.5%+9.2%
GLD CommoditiesSPDR Gold Shares0.02+120%0.93+26.7%−1.9%+8.0%+4.9%——————24.1%+8.4%

Stocks

InvestmentCorrelation5Y returnSharpe202420182016200820042003200220011998199780/20 mix volatility80/20 mix annual return
REGN Regeneron Pharmaceuticals, Inc. (this page)1.00+44.5%0.39−18.9%−0.7%−32.4%−24.0%−37.4%−20.6%−34.3%−20.2%−13.8%−46.9%29.7%+4.8%
CAH Medical - DistributionCardinal Health, Inc.0.11+471%1.54+19.0%−24.5%−17.5%−39.6%−4.7%+3.5%−8.3%−2.5%+51.7%+29.1%24.9%+11.9%
CLS Hardware, Equipment & PartsCelestica Inc.-0.10+2,780%1.43+215%−16.3%+7.4%−20.5%−6.4%+6.9%−65.1%−25.6%——25.4%+24.9%
MCK Medical - DistributionMcKesson Corporation0.17+397%1.41+23.7%−28.4%−28.3%−40.4%−1.4%+19.9%−27.2%+4.9%+46.9%+96.3%25.1%+11.3%
FIX Engineering & ConstructionComfort Systems USA, Inc.-0.04+1,452%1.41+107%+0.8%+18.3%−15.2%+40.0%+63.6%−9.4%+73.7%−9.5%—25.0%+20.7%
MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation0.31+660%1.39−4.0%−8.2%+0.7%———————26.5%+13.6%
Open these 14 in EasyCompare

Common questions

What was REGN's worst drawdown?

REGN's deepest decline since it began trading in 1991 was 91.8%, from February 2000 to April 2005. It took about six years from the low to climb back to its old high.

What were REGN's best and worst years?

Over 29 full calendar years, REGN's best year was 2012, when it returned 209%. Its worst was 1997, with a return of -46.9%.

Is there a better investment than REGN?

Among REGN's popular alternatives, AMGN, GILD and VRTX earned more than REGN with less volatility over the past 5 years. AMGN returned 20.1% a year at 24.9% volatility, against 7.6% a year at 31.2%. Looking beyond its popular alternatives, MRK (pharmaceuticals) and TAK (specialty pharmaceuticals) earned more than REGN with less volatility over the past 5 years. MRK returned 16.1% a year at 24.8% volatility, against 7.6% a year at 31.2%.

Is REGN more volatile than the S&P 500?

Yes. REGN's volatility over the past 5 years was 31.2%, 1.8 times the S&P 500's 17.2%. Volatility measures how widely returns swing around their average: in roughly two years out of three, REGN's return lands within 31.2% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

What is REGN's Sharpe ratio?

REGN's Sharpe ratio over the past 5 years was 0.39, against 0.78 for the S&P 500, so REGN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

How correlated is REGN with the S&P 500?

Over the past 5 years, REGN's monthly returns had a correlation of 0.08 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against REGN instead: the lower it is, the more that option would diversify a REGN holding.

What are the best alternatives to REGN?

Of the 22 popular alternatives we compared, nine outperformed REGN in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: HALO, LLY and EXEL.

Did REGN outperform the S&P 500?

REGN finished ahead of the S&P 500 (SPY) in 17 of 29 full calendar years. In 2025, it returned +9.0%, against +17.7% for the index.

How did REGN do in stock market crashes?

REGN fell less than the S&P 500 (SPY) in four of the ten major crashes it has traded through, and further in six. The clearest case was the 2015 China and oil sell-off, when REGN fell 37.7% and the S&P 500 fell 12.8%.

What diversifies REGN?

These had a low correlation with REGN over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.24), DXJ (correlation 0.05) and EMLP (correlation 0.10); among large stocks, CAH (correlation 0.11), CLS (correlation -0.10) and MCK (correlation 0.17). A correlation near zero means the two have moved largely independently.

How we measure

More research

Popular alternatives to REGN

Other stocks and ETFs